Stay updated with breaking news from Dcph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Dean Seal Shares of Deciphera Pharmaceuticals jumped after the company said a trial of vimseltinib, its treatment for tenosynovial giant cell tumors, met...
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as $10.24 and last traded at $10.55, with a volume of 14011 shares changing hands. The stock had previously closed at $10.57. Analyst Ratings Changes DCPH has been the subject of a […]
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the […]
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) traded down 6.3% on Wednesday . The stock traded as low as $14.44 and last traded at $14.51. 150,124 shares were traded during mid-day trading, a decline of 77% from the average session volume of 645,505 shares. The stock had previously closed at $15.48. Wall […]